{"name": "Synta Pharmaceuticals",
 "permalink": "synta-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/synta-pharmaceuticals",
 "homepage_url": "http://www.syntapharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2000,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "ir@syntapharma.com",
 "phone_number": "781.274.8200",
 "description": "",
 "created_at": "Tue Jan 12 04:26:13 UTC 2010",
 "updated_at": "Thu Jan 13 03:01:22 UTC 2011",
 "overview": "\u003Cp\u003ESynta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       68],
      "assets/images/resized/0007/2954/72954v1-max-150x150.jpg"],
     [[174,
       79],
      "assets/images/resized/0007/2954/72954v1-max-250x250.jpg"],
     [[174,
       79],
      "assets/images/resized/0007/2954/72954v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "Safi",
      "last_name": "R. Bahcall",
      "permalink": "safi-r-bahcall",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Keith",
      "last_name": "Ehrlich",
      "permalink": "keith-ehrlich",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$26.9M",
 "funding_rounds":
  [{"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2010/01/04/daily61-Synta-makes-25M-public-stock-offering.html",
    "source_description": "Synta makes $25M public stock offering",
    "raised_amount": 23100000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 1,
    "funded_day": 8,
    "investments":
     []},
   {"round_code": "unattributed",
    "source_url": "http://www.masshightech.com/stories/2010/01/18/daily10-Synta-nets-another-375M-in-follow-on-offering.html",
    "source_description": "Synta nets another $3.75M in follow-on offering",
    "raised_amount": 3750000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 1,
    "funded_day": 19,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "45 Hartwell Avenue",
    "address2": "",
    "zip_code": "02421",
    "city": "Lexington",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "has taken in $1 million from a joint collaboration agreement with the Multiple Myeloma Research Foundation (MMRF) for the development of a drug to treat multiple myeloma",
    "stoned_year": 2011,
    "stoned_month": 1,
    "stoned_day": 12,
    "source_url": "http://www.masshightech.com/stories/2011/01/10/daily29-Synta-snags-1M-for-blood-cancer-drug-trial.html",
    "source_text": null,
    "source_description": "Synta snags $1M for blood cancer drug trial",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Synta Pharmaceuticals",
      "permalink": "synta-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:SNTA"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        82],
       "assets/images/resized/0007/2953/72953v1-max-150x150.jpg"],
      [[250,
        137],
       "assets/images/resized/0007/2953/72953v1-max-250x250.jpg"],
      [[450,
        246],
       "assets/images/resized/0007/2953/72953v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}